Histogen Inc

Histogen — Conatus Pharmaceuticals — Corporate Update (May 2019)

27 slides from Histogen's corporate update, May 15, 2019

  1. Slide 1: Inflammasome Program

    May 2019 Inflammasome Program Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products,

  3. Slide 3: Highlights of Conatus Approach

    Highlights of Conatus Approach Like inflammasome intervention, caspase 1 inhibition is a small molecule strategy to block the formation of IL-1b Additional benefits include IL-18 inhibition, gasdermin D inhibition, and a decrease in inflammation driven cell death (pyroptosis) vs. IL-1b blocking agen

  4. Slide 4: IL-1β Blocking Agents: Set the Stage for Next Generation Products

    IL-1β Blocking Agents: Set the Stage for Next Generation Products Multiple approved biologic agents that block IL-1β Canakinumab (Ilaris ®) monoclonal antibody targeted at IL-1β Anakinra (Kineret ®) interleukin-1 receptor antagonist Rilonacept (Arcalyst ®) IL-1 Trap Global sales of over $700 million

  5. Slide 5: IL-1b: Driven by Multiple Inflammasomes

    IL-1b: Driven by Multiple Inflammasomes Solberger G, et al. Innate Immun. 2014, p115-125.

  6. Slide 6: Disease Areas Implicated in the Inflammasome Pathway

    Disease Areas Implicated in the Inflammasome Pathway Therapeutic areas Disease Conditions Autoinflammatory Cryopyrin-Associated Periodic Syndromes Muckle-Wells Syndrome Schnitzler’s Syndrome Familial Mediterranean Fever Macrophage Activation Syndrome Gastroenterology Crohn's Ulcerative Colitis IBD R

  7. Slide 7: IL-1b Blocking Agents: Development Pathway Defined

    IL-1b Blocking Agents: Development Pathway Defined* Wide scope of clinical indications and therapeutic validation All agents given by injection (not orally active) Most recent success – Novartis, Ilaris® 2017: Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) Confidential Kineret® Ilar

  8. Slide 8: The Future of IL-1β Blocking May Be in Cancer

    The Future of IL-1β Blocking May Be in Cancer

  9. Slide 9: Inflammasome Companies: Investor and Pharma Interest

    Inflammasome Companies: Investor and Pharma Interest IFM TRE raised a $31mm Series A in 2018 from Atlas, Abingworth, and BMS. Acquisition by Novartis announced April 2019 for $310M upfront (Phase 1) and up to $1.6B total. Jecure Therapeutics raised a $30mm Series A from Versant in 2017. Acquired by

  10. Slide 10: Caspase 1 Inhibitors Target Inflammasome Pathway at Optimal Intervention Point

    (Novartis) (Amgen) (Regeneron) Caspase 1 Inhibitors Caspase 1 Inhibitors Target Inflammasome Pathway at Optimal Intervention Point We believe a caspase 1 selective small molecule inhibitor can be a safe and efficacious agent for intervention in the inflammasome pathway Modified from Mangan M et al.

  11. Slide 11: Caspase Inhibition Improves Survival Better than Blocking IL-1β, IL-18 or Both

    Caspase 1 Inhibition Improves Survival Better than Blocking IL-1β, IL-18 or Both Constitutively active NLRP3 (FCAS model) results in chronic activation of caspase 1 Leads to production of IL-1β and IL-18 Leads to pyroptotic cell death via gasdermin D cleavage Caspase 1 KO showed improved survival ov

  12. Slide 12: Targeting IL-1b and Inflammation via Caspase Inhibition

    Targeting IL-1b and Inflammation via Caspase 1 Inhibition IL-1b is a validated inflammatory target – high interest in the pathway NLRP3 Caspase 1 IL-1β Pro caspase 1 Pro IL-1β Inflammation NLRP3 companies Biologic products (Novartis) (Amgen) (Regeneron) “Detector” senses stress signal “Master” infla

  13. Slide 13: CTS-2090 Bridging the gap between Detector and Master

    CTS-2090 Bridging the gap between “Detector” and “Master”

  14. Slide 14: Conatus' Caspase Inhibitor Portfolio

    Conatus’ Caspase 1 Inhibitor Portfolio Designed highly selective caspase 1 inhibitors Incorporated novel chemistry to remove activity against apoptotic caspases Maintained sub-nanomolar activity against caspase 1 Inhibits downstream IL-1b (a clinically validated target) Demonstrated functional activ

  15. Slide 15: Conatus' Lead Caspase Inhibitor: CTS-2090

    Conatus’ Lead Caspase 1 Inhibitor: CTS-2090 Potency Sub-nanomolar IC50 against human caspase 1 Sub-micromolar IC50 in THP 1 cells Selectivity Broad panel of receptors and enzymes: >100,000 fold selectivity over caspase 1 No anti-apoptotic activity in cells at 10mM: enzyme selectivity reflected in ce

  16. Slide 16: CTS-2090: Enzymatic Potency and Selectivity

    CTS-2090: Enzymatic Potency and Selectivity CTS-2090 is a potent, selective and irreversible inhibitor of caspase 1 Additional analogs have similar potency Target: IDN-7314+ CTS-2090 Caspase 1 <5.08E-11 5.60E-11 Caspase 3 1.60E-09 * Caspase 6 2.14E-08 * Caspase 7 4.63E-10 * CTS-2090: IC50 values aga

  17. Slide 17: CTS-2090: Potency and Selectivity Validated in Cell-based Functional Assays

    CTS-2090: Potency and Selectivity Validated in Cell-based Functional Assays CTS-2090 is a potent inhibitor of LPS-stimulated NLRP3 driven IL-1b production in THP 1 cells IC50 value similar to that of the reference pan-caspase inhibitor, IDN-7314 CTS-2090 does not protect Jurkat cells from a-Fas – in

  18. Slide 18: CTS-2090: Not Active in an Animal Model of Apoptosis

    CTS-2090: Not Active in an Animal Model of Apoptosis In vivo activity is consistent with cellular and enzymatic selectivity profiles CTS-2090 does not protect against apoptosis induced by aFas in mice IDN-7314 is completely protective against aFas induced apoptosis in mice CTS-2090 (10 mg/Kg) and ID

  19. Slide 19: CTS-2090: Reduces IL-1b and IL-18 in an NLRP3 Driven Inflammasome Model

    CTS-2090: Reduces IL-1b and IL-18 in an NLRP3 Driven Inflammasome Model CTS-2090 reduces IL-1b and IL-18 similar to MCC950 in an NLRP3 activation model of peritonitis CTS-2090 and MCC950 were administered i.p. 1 hour post-LPS injection At 2h post-LPS, ATP was administered and 30 min. later peritonea

  20. Slide 20: CTS-2090: Reduces IL-1b in the MSU Crystal-Induced Gout Model

    CTS-2090: Reduces IL-1b in the MSU Crystal-Induced Gout Model CTS-2090 (10mg/Kg) reduced IL-1b similar to MCC950 (40mg/Kg) CTS-2090 and MCC950 were administered i.p. 30 min. prior to MSU Peritoneal lavage fluid was collected 6h post-MSU injection and analyzed for IL-1b * * Percent reduction *

  21. Slide 21: CTS-2090: Tissue Distribution and Metabolic Stability

    Intestine Liver tissue CTS-2090: Tissue Distribution and Metabolic Stability Good oral bioavailability: 45% in rodent Higher tissue distribution of parent molecule in colon than plasma or liver ~1:1 distribution plasma / liver Excellent metabolic stability in rodent tissue (liver and intestine)

  22. Slide 22: CTS-2090: Reduces Disease Severity in the Rat TNBS Colitis Model

    CTS-2090: Reduces Disease Severity in the Rat TNBS Colitis Model CTS-2090 reduces TNBS-induced weight loss as effectively as prednisolone at day 7 Oral administration of CTS-2090 or Prednisolone initiated 1 day post-TNBS induced colitis and dosed for 6 days. Animal weights monitored daily

  23. Slide 23: Autoinflammatory Diseases as Initial Clinical Target for CTS-2090

    Autoinflammatory Diseases as Initial Clinical Target for CTS-2090 Single-gene mutations that activate inflammasomes and result in IL-1β production Spectrum of diseases with variable organ system involvement, severity and age of onset Cryopyrin-associated periodic syndromes (CAPS) Familial cold urtic

  24. Slide 24: Overview of CTS-2090 Development Plan

    Overview of CTS-2090 Development Plan Phase 1, part A Single-dose PK Phase 1, part B Multiple-dose PK Phase 2a Multiple-dose/endotoxin challenge study in normal volunteers Phase 2 PoC Autoinflammatory Diseases Other Potential Indications IBD/Crohn’s Gout flares Oncology PK, Safety, Tolerability Dose

  25. Slide 25: Intellectual Property

    Intellectual Property Two new composition of matter provisional patent applications filed Applications describe two broad and distinct non-overlapping chemical series of inhibitors Additional novel chemical classes have been identified. New provisional applications planned.

  26. Slide 26: Highlights of Conatus Approach

    Highlights of Conatus Approach Like inflammasome intervention, caspase 1 inhibition is a small molecule strategy to block the formation of IL-1b Additional benefits include IL-18 inhibition, gasdermin D inhibition, and a decrease in inflammation driven cell death (pyroptosis) vs. IL-1b blocking agen

  27. Slide 27: Conatus Pharmaceuticals

    Conatus Pharmaceutical

Conatus Pharmaceuticals — Corporate Update (May 2019) on 6ix